ArticleInternational journal of nanomedicine2015
Peptide gH625 enters into neuron and astrocyte cell lines and crosses the blood-brain barrier in rats.
Article in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Bio-inspired self-assembly of omega-3 fatty acids and peptides for responsive drug delivery.International journal of pharmaceutics: X · 2026Article
- Ultrasound-triggered amygdalin drug release across U-87 glioblastoma cell lines from gH625-tagged phase convertible nanodroplets.Scientific reports · 2026Article
- Synergistic Cancer Metabolic Therapy via Co-Delivery of 3-Bromopyruvate and Temozolomide with a Supramolecular Shuttle.ACS applied materials & interfaces · 2025Article
- Engineering Multifunctional Peptide-Decorated Nanofibers for Targeted Delivery of Temozolomide across the Blood-Brain Barrier.Molecular pharmaceutics · 2025Article
- The synergistic antibacterial activity and mechanism of colistin-oxethazaine combination against gram-negative pathogens.Frontiers in pharmacology · 2024Article
- Neuroprotective Effects of gH625-lipoPACAP in an In Vitro Fluid Dynamic Model of Parkinson's Disease.Biomedicines · 2022Article
- Functionalized Platinum Nanoparticles with Biomedical Applications.International journal of molecular sciences · 2022Review
- Design and Validation of Nanofibers Made of Self-Assembled Peptides to Become Multifunctional Stimuli-Sensitive Nanovectors of Anticancer Drug Doxorubicin.Pharmaceutics · 2022Article
- An Overview of Nanotechnologies for Drug Delivery to the Brain.Pharmaceutics · 2022Review
- gH625-liposomes deliver PACAP through a dynamicFrontiers in physiology · 2022Article
- Astrocyte Mitochondria in White-Matter Injury.Neurochemical research · 2021Review
- Challenges and Opportunities of Targeting Astrocytes to Halt Neurodegenerative Disorders.Cells · 2021Review
- Effect of the Combination of Levofloxacin with Cationic Carbosilane Dendron and Peptide in the Prevention and Treatment ofPolymers · 2021Article
- Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Review
- Diversity of Reactive Astrogliosis in CNS Pathology: Heterogeneity or Plasticity?Frontiers in cellular neuroscience · 2021Review
- Astrocyte mitochondria: Central players and potential therapeutic targets for neurodegenerative diseases and injury.Ageing research reviews · 2020Article
- Eradication of Candida albicans persister cell biofilm by the membranotropic peptide gH625.Scientific reports · 2020Article
- Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis.Materials today. Bio · 2020Review
- Quantum dots functionalized with gH625 attenuate QDs oxidative stress and lethality in Caenorhabditis elegans: a model system.Ecotoxicology (London, England) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide gH625, derived from glycoprotein H of herpes simplex virus type 1, can enter cells efficiently and deliver a cargo. Nanoparticles armed with gH625 are able to cross an in vitro model of the blood-brain barrier (BBB). In the present study, in vitro experiments were performed to investigate whether gH625 can enter and accumulate in neuron and astrocyte cell lines. The ability of gH625 to cross the BBB in vivo was also evaluated. gH625 was administered in vivo to rats and its presence in the liver and in the brain was detected. Within 3.5 hours of intravenous administration, gH625 can be found beyond the BBB in proximity to cell neurites. gH625 has no toxic effects in vivo, since it does not affect the maximal oxidative capacity of the brain or the mitochondrial respiration rate. Our data suggest that gH625, with its ability to cross the BBB, represents a novel nanocarrier system for drug delivery to the central nervous system. These results open up new possibilities for direct delivery of drugs into patients in the field of theranostics and might address the treatment of several human diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.